Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash from Financing Activities (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Cash from Financing Activities for 9 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 29.62% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.9 million through Dec 2025, down 11.56% year-over-year, with the annual reading at $22.9 million for FY2025, 11.56% down from the prior year.
  • Cash from Financing Activities hit $2.8 million in Q4 2025 for Protagonist Therapeutics, down from $5.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $125.4 million in Q2 2021 to a low of $527000.0 in Q4 2023.
  • Historically, Cash from Financing Activities has averaged $18.4 million across 5 years, with a median of $3.5 million in 2024.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 99.46% in 2022 and later skyrocketed 15807.65% in 2023.
  • Year by year, Cash from Financing Activities stood at $2.2 million in 2021, then plummeted by 74.55% to $553000.0 in 2022, then fell by 4.7% to $527000.0 in 2023, then soared by 664.9% to $4.0 million in 2024, then decreased by 29.62% to $2.8 million in 2025.
  • Business Quant data shows Cash from Financing Activities for PTGX at $2.8 million in Q4 2025, $5.7 million in Q3 2025, and $2.9 million in Q2 2025.